Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23 (original) (raw)

• Beenken, A. & Mohammadi, M. The FGF family: biology, pathophysiology and therapy. Nat. Rev. Drug Discov. 8, 235–253 (2008).
  Google Scholar
• Itoh, N. & Ornitz, D. M. Evolution of the Fgf and Fgfr gene families. Trends Genet. 20, 563–569 (2004).
  CAS PubMed Google Scholar
• Itoh, N. & Ornitz, D. M. Functional evolutionary history of the mouse Fgf gene family. Dev. Dyn. 237, 18–27 (2008).
  CAS PubMed Google Scholar
• Ornitz, D. M. et al. Receptor specificity of the fibroblast growth factor family. J. Biol. Chem. 271, 15292–15297 (1996).
  CAS PubMed Google Scholar
• Ornitz, D. M. FGFs, heparan sulfate and FGFRs: complex interactions essential for development. Bioessays 22, 108–112 (2000).
  CAS PubMed Google Scholar
• Mohammadi, M., Olsen, S. K. & Ibrahimi, O. A. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev. 16, 107–137 (2005).
  CAS PubMed Google Scholar
• Itoh, N. Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease. Cell Tissue Res. 342, 1–11 (2010).
  CAS PubMed PubMed Central Google Scholar
• Goetz, R. et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol. Cell. Biol. 27, 3417–3428 (2007).
  CAS PubMed PubMed Central Google Scholar
• Zhang, X. et al. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J. Biol. Chem. 281, 15694–15700 (2006).
  CAS PubMed Google Scholar
• Kurosu, H. et al. Regulation of fibroblast growth factor-23 signaling by klotho. J. Biol. Chem. 281, 6120–6123 (2006). This paper provides the first evidence that FGF23 requires α-klotho to activate FGFR.
  CAS PubMed Google Scholar
• Ogawa, Y. et al. βKlotho is required for metabolic activity of fibroblast growth factor 21. Proc. Natl Acad. Sci. USA 104, 7432–7437 (2007).
  CAS PubMed PubMed Central Google Scholar
• Urakawa, I. et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444, 770–774 (2006). This work identifies the requirement for klotho to convert canonical FGF into endocrine FGFs.
  CAS PubMed Google Scholar
• Wu, X. et al. Co-receptor requirements for fibroblast growth factor-19 signaling. J. Biol. Chem. 282, 29069–29072 (2007).
  CAS PubMed Google Scholar
• Ding, X. et al. βKlotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell. Metab. 16, 387–393 (2012).
  CAS PubMed PubMed Central Google Scholar
• Kharitonenkov, A. et al. FGF-21/FGF-21 receptor interaction and activation is determined by βKlotho. J. Cell. Physiol. 215, 1–7 (2008).
  CAS PubMed Google Scholar
• Lin, B. C., Wang, M., Blackmore, C. & Desnoyers, L. R. Liver-specific activities of FGF19 require Klotho beta. J. Biol. Chem. 282, 27277–27284 (2007).
  CAS PubMed Google Scholar
• Kurosu, H. et al. Tissue-specific expression of βKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J. Biol. Chem. 282, 26687–26695 (2007). This work establishes β-klotho tissue-specific expression as a major determinant of FGF19 and FGF21 metabolic activity.
  CAS PubMed Google Scholar
• Adams, A. C., Cheng, C. C., Coskun, T. & Kharitonenkov, A. FGF21 requires βklotho to act in vivo. PLoS ONE 7, e49977 (2012).
  CAS PubMed PubMed Central Google Scholar
• Yang, C. et al. Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. PLoS ONE 7, e33870 (2012).
  CAS PubMed PubMed Central Google Scholar
• Inagaki, T. et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell. Metab. 2, 217–225 (2005). This is the first elucidation of FGF15/19 in bile acid metabolism.
  CAS PubMed Google Scholar
• Choi, M. et al. Identification of a hormonal basis for gallbladder filling. Nat. Med. 12, 1253–1255 (2006).
  CAS PubMed Google Scholar
• Holt, J. A. et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 17, 1581–1591 (2003).
  CAS PubMed PubMed Central Google Scholar
• Song, K. H., Li, T., Owsley, E., Strom, S. & Chiang, J. Y. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7α-hydroxylase gene expression. Hepatology 49, 297–305 (2009).
  CAS PubMed Google Scholar
• Potthoff, M. J. et al. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathway. Cell. Metab. 13, 729–738 (2011).
  CAS PubMed PubMed Central Google Scholar
• Kir, S. et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 331, 1621–1624 (2011).
  CAS PubMed PubMed Central Google Scholar
• Xu, J. et al. Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models — association with liver and adipose tissue effects. Am. J. Physiol. Endocrinol. Metab. 297, E1105–E1114 (2009).
  CAS PubMed Google Scholar
• Kharitonenkov, A. et al. FGF-21 as a novel metabolic regulator. J. Clin. Invest. 115, 1627–1635 (2005).
  CAS PubMed PubMed Central Google Scholar
• Coskun, T. et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149, 6018–6027 (2008).
  CAS PubMed Google Scholar
• Bhatnagar, S., Damron, H. A. & Hillgartner, F. B. Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis. J. Biol. Chem. 284, 10023–10033 (2009).
  CAS PubMed PubMed Central Google Scholar
• Xu, J. et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58, 250–259 (2009).
  CAS PubMed PubMed Central Google Scholar
• Shimada, T. et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J. Clin. Invest. 113, 561–568 (2004).
  CAS PubMed PubMed Central Google Scholar
• Potthoff, M. J. et al. FGF21 induces PGC-1α and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc. Natl Acad. Sci. USA 106, 10853–10858 (2009). This work elucidates the role of FGF21 in the regulation of carbohydrate and fatty acid metabolism.
  CAS PubMed PubMed Central Google Scholar
• Inagaki, T. et al. Endocrine regulation of the fasting response by PPARα-mediated induction of fibroblast growth factor 21. Cell. Metab. 5, 415–425 (2007).
  CAS PubMed Google Scholar
• Badman, M. K. et al. Hepatic fibroblast growth factor 21 is regulated by PPARα and is a key mediator of hepatic lipid metabolism in ketotic states. Cell. Metab. 5, 426–437 (2007). This work establishes FGF21 as a crucial hormone in the body's adaptation to fasting.
  CAS PubMed Google Scholar
• White, K. E. et al. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int. 60, 2079–2086 (2001).
  CAS PubMed Google Scholar
• Shimada, T. et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc. Natl Acad. Sci. USA 98, 6500–6505 (2001).
  CAS PubMed PubMed Central Google Scholar
• Benet- Pagès, A., Orlik, P., Strom, T. M. & Lorenz-Depiereux, B. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum. Mol. Genet. 14, 385–390 (2005).
  Google Scholar
• Modica, S. et al. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology 142, 355–365 (2012). This study provides the first evidence that FGF19 administration protects mice from cholestasis.
  CAS PubMed Google Scholar
• Luo, J. et al. A nontumorigenic variant of FGF19 treats cholestatic liver diseases. Sci. Transl. Med. 6, 247ra100 (2014). This is the first evidence that an FGF19 analogue lowers bile acid synthesis in humans.
  PubMed Google Scholar
• Degirolamo, C. et al. Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation. Hepatology 61, 161–170 (2015).
  CAS PubMed Google Scholar
• Gaich, G. et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell. Metab. 18, 333–340 (2013). This is the first study reporting the effects of an FGF21 analogue in humans.
  CAS PubMed Google Scholar
• McWhirter, J. R., Goulding, M., Weiner, J. A., Chun, J. & Murre, C. A novel fibroblast growth factor gene expressed in the developing nervous system is a downstream target of the chimeric homeodomain oncoprotein E2A–Pbx1. Development 124, 3221–3232 (1997).
  CAS PubMed Google Scholar
• Nishimura, T., Utsunomiya, Y., Hoshikawa, M., Ohuchi, H. & Itoh, N. Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain. Biochim. Biophys. Acta 1444, 148–151 (1999).
  CAS PubMed Google Scholar
• Katoh, M. & Katoh, M. Evolutionary conservation of CCND1-ORAOV1-FGF19-FGF4 locus from zebrafish to human. Int. J. Mol. Med. 12, 45–50 (2003).
  CAS PubMed Google Scholar
• Yamashita, T., Yoshioka, M. & Itoh, N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem. Biophys. Res. Commun. 277, 494–498 (2000).
  CAS PubMed Google Scholar
• Nishimura, T., Nakatake, Y., Konishi, M. & Itoh, N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim. Biophys. Acta 1492, 203–206 (2000).
  CAS PubMed Google Scholar
• Tacer, K. F. et al. Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol. Endocrinol. 24, 2050–2064 (2010).
  CAS Google Scholar
• Wright, T. J. et al. Mouse FGF15 is the ortholog of human and chick FGF19, but is not uniquely required for otic induction. Dev. Biol. 269, 264–275 (2004).
  CAS PubMed Google Scholar
• Xie, M. H. et al. FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 11, 729–735 (1999).
  CAS PubMed Google Scholar
• Wente, W. et al. Fibroblast growth factor-21 improves pancreatic β-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 55, 2470–2478 (2006).
  CAS PubMed Google Scholar
• Zhang, X. et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57, 1246–1253 (2008).
  CAS PubMed Google Scholar
• Muise, E. S. et al. Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor γ and altered metabolic states. Mol. Pharmacol. 74, 403–412 (2008).
  CAS PubMed Google Scholar
• Kharitonenkov, A. & Shanafelt, A. B. FGF21: a novel prospect for the treatment of metabolic diseases. Curr. Opin. Investig. Drugs 10, 359–364 (2009).
  CAS PubMed Google Scholar
• Izumiya, Y. et al. FGF21 is an Akt-regulated myokine. FEBS Lett. 582, 3805–3810 (2008).
  CAS PubMed PubMed Central Google Scholar
• Riminucci, M. et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J. Clin. Invest. 112, 683–692 (2003).
  CAS PubMed PubMed Central Google Scholar
• Liu, S. et al. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J. Biol. Chem. 278, 37419–37426 (2003).
  CAS PubMed Google Scholar
• Nagano, M. et al. Regulation of bile acid synthesis under reconstructed enterohepatic circulation in rats. Steroids 69, 701–709 (2004).
  CAS PubMed Google Scholar
• Kim, I. et al. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J. Lipid Res. 48, 2664–2672 (2007).
  CAS PubMed Google Scholar
• Miyata, M. et al. Involvement of multiple elements in FXR-mediated transcriptional activation of FGF19. J. Steroid Biochem. Mol. Biol. 132, 41–47 (2012).
  CAS PubMed Google Scholar
• Schmidt, D. R. et al. Regulation of bile acid synthesis by fat-soluble vitamins A and D. J. Biol. Chem. 285, 14486–14494 (2010).
  CAS PubMed PubMed Central Google Scholar
• Henkel, A. S., Anderson, K. A., Dewey, A. M., Kavesh, M. H. & Green, R. M. A chronic high-cholesterol diet paradoxically suppresses hepatic CYP7A1 expression in FVB/NJ mice. J. Lipid Res. 52, 289–298 (2011).
  CAS PubMed PubMed Central Google Scholar
• Miyata, M., Hata, T., Yamazoe, Y. & Yoshinari, K. SREBP-2 negatively regulates FXR-dependent transcription of FGF19 in human intestinal cells. Biochem. Biophys. Res. Commun. 443, 477–482 (2014).
  CAS PubMed Google Scholar
• Wistuba, W., Gnewuch, C., Liebisch, G., Schmitz, G. & Langmann, T. Lithocholic acid induction of the FGF19 promoter in intestinal cells is mediated by PXR. World J. Gastroenterol. 13, 4230–4235 (2007).
  CAS PubMed PubMed Central Google Scholar
• Shimizu, M., Li, J., Maruyama, R., Inoue, J. & Sato, R. FGF19 (fibroblast growth factor 19) as a novel target gene for activating transcription factor 4 in response to endoplasmic reticulum stress. Biochem. J. 450, 221–229 (2013).
  CAS PubMed Google Scholar
• Vergnes, L., Lee, J. M., Chin, R. G., Auwerx, J. & Reue, K. Diet1 functions in the FGF15/19 enterohepatic signaling axis to modulate bile acid and lipid levels. Cell. Metab. 17, 916–928 (2013).
  CAS PubMed PubMed Central Google Scholar
• Wu, X. et al. Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice. Proc. Natl Acad. Sci. USA 106, 14379–14384 (2009).
  CAS PubMed PubMed Central Google Scholar
• Fu, L. et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 145, 2594–2603 (2004).
  CAS PubMed Google Scholar
• Kong, B. et al. Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice. Hepatology 56, 1034–1043 (2012).
  CAS PubMed Google Scholar
• Li, S. et al. Cytoplasmic tyrosine phosphatase Shp2 coordinates hepatic regulation of bile acid and FGF15/19 signaling to repress bile acid synthesis. Cell. Metab. 20, 320–332 (2014).
  CAS PubMed PubMed Central Google Scholar
• Wang, C. et al. Hepatocyte FRS2α is essential for the endocrine fibroblast growth factor to limit the amplitude of bile acid production induced by prandial activity. Curr. Mol. Med. 14, 703–711 (2014).
  CAS PubMed PubMed Central Google Scholar
• Yu, C. et al. Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J. Biol. Chem. 275, 15482–15489 (2000).
  CAS PubMed Google Scholar
• Ito, S. et al. Impaired negative feedback suppression of bile acid synthesis in mice lacking βKlotho. J. Clin. Invest. 115, 2202–2208 (2005).
  CAS PubMed PubMed Central Google Scholar
• Tomiyama, K. et al. Relevant use of Klotho in FGF19 subfamily signaling system in vivo. Proc. Natl Acad. Sci. USA 107, 1666–1671 (2010).
  CAS PubMed PubMed Central Google Scholar
• Yu, C., Wang, F., Jin, C., Huang, X. & McKeehan, W. L. Independent repression of bile acid synthesis and activation of c-Jun N-terminal kinase (JNK) by activated hepatocyte fibroblast growth factor receptor 4 (FGFR4) and bile acids. J. Biol. Chem. 280, 17707–17714 (2005).
  CAS PubMed Google Scholar
• Kir, S., Zhang, Y., Gerard, R. D., Kliewer, S. A. & Mangelsdorf, D. J. Nuclear receptors HNF4α and LRH-1 cooperate in regulating Cyp7a1 in vivo. J. Biol. Chem. 287, 41334–41341 (2012).
  CAS PubMed PubMed Central Google Scholar
• Nitta, M., Ku, S., Brown, C., Okamoto, A. Y. & Shan, B. CPF: an orphan nuclear receptor that regulates liver-specific expression of the human cholesterol 7α-hydroxylase gene. Proc. Natl Acad. Sci. USA 96, 6660–6665 (1999).
  CAS PubMed PubMed Central Google Scholar
• Stroup, D. & Chiang, J. Y. HNF4 and COUP-TFII interact to modulate transcription of the cholesterol 7α-hydroxylase gene (CYP7A1). J. Lipid Res. 41, 1–11 (2000).
  CAS PubMed Google Scholar
• Miao, J. et al. Bile acid signaling pathways increase stability of small heterodimer partner (SHP) by inhibiting ubiquitin-proteasomal degradation. Genes Dev. 23, 986–996 (2009).
  CAS PubMed PubMed Central Google Scholar
• Lee, Y. K. et al. Liver receptor homolog-1 regulates bile acid homeostasis but is not essential for feedback regulation of bile acid synthesis. Mol. Endocrinol. 22, 1345–1356 (2008).
  CAS PubMed PubMed Central Google Scholar
• Potthoff, M. J., Kliewer, S. A. & Mangelsdorf, D. J. Endocrine fibroblast growth factors 15/19 and 21: from feast to famine. Genes Dev. 26, 312–324 (2012).
  CAS PubMed PubMed Central Google Scholar
• Tomlinson, E. et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 143, 1741–1747 (2002).
  CAS PubMed Google Scholar
• Wu, A. L. et al. FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways. PLoS ONE 6, e17868 (2011).
  CAS PubMed PubMed Central Google Scholar
• Yu, X. X. et al. Peripheral reduction of FGFR4 with antisense oligonucleotides increases metabolic rate and lowers adiposity in diet-induced obese mice. PLoS ONE 8, e66923 (2013).
  PubMed PubMed Central Google Scholar
• Ge, H. et al. Fibroblast growth factor receptor 4 (FGFR4) deficiency improves insulin resistance and glucose metabolism under diet-induced obesity conditions. J. Biol. Chem. 289, 30470–30480 (2014).
  CAS PubMed PubMed Central Google Scholar
• Marcelin, G. et al. Central action of FGF19 reduces hypothalamic AGRP/NPY neuron activity and improves glucose metabolism. Mol. Metab. 3, 19–28 (2014).
  CAS PubMed Google Scholar
• Ryan, K. K. et al. Fibroblast growth factor-19 action in the brain reduces food intake and body weight and improves glucose tolerance in male rats. Endocrinology 154, 9–15 (2013).
  CAS PubMed Google Scholar
• Morton, G. J. et al. FGF19 action in the brain induces insulin-independent glucose lowering. J. Clin. Invest. 123, 4799–4808 (2013).
  CAS PubMed PubMed Central Google Scholar
• Katafuchi, T. et al. Detection of FGF15 in plasma by stable isotope standards and capture by anti-peptide antibodies and targeted mass spectrometry. Cell. Metab. 21, 898–904 (2015).
  CAS PubMed PubMed Central Google Scholar
• Lundasen, T., Galman, C., Angelin, B. & Rudling, M. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J. Intern. Med. 260, 530–536 (2006).
  CAS PubMed Google Scholar
• Schaap, F. G., van der Gaag, N. A., Gouma, D. J. & Jansen, P. L. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 49, 1228–1235 (2009).
  CAS PubMed Google Scholar
• Reiche, M. et al. Fibroblast growth factor 19 serum levels: relation to renal function and metabolic parameters. Horm. Metab. Res. 42, 178–181 (2010).
  CAS PubMed Google Scholar
• Lenicek, M. et al. Bile acid malabsorption in inflammatory bowel disease: assessment by serum markers. Inflamm. Bowel Dis. 17, 1322–1327 (2011).
  PubMed Google Scholar
• Walters, J. R. et al. A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clin. Gastroenterol. Hepatol 7, 1189–1194 (2009).
  CAS PubMed Google Scholar
• Schreuder, T. C. et al. The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. Am. J. Physiol. Gastrointest. Liver Physiol. 298, G440–G445 (2010).
  CAS PubMed Google Scholar
• Mráz, M. et al. Serum concentrations of fibroblast growth factor 19 in patients with obesity and type 2 diabetes mellitus: the influence of acute hyperinsulinemia, very-low calorie diet and PPAR-α agonist treatment. Physiol. Res. 60, 627–636 (2011).
  PubMed Google Scholar
• Nicholes, K. et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am. J. Pathol. 160, 2295–2307 (2002).
  CAS PubMed PubMed Central Google Scholar
• Miura, S. et al. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC Cancer 12, 56 (2012).
  CAS PubMed PubMed Central Google Scholar
• Wu, X. et al. Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19). Proc. Natl Acad. Sci. USA 107, 14158–14163 (2010).
  CAS PubMed PubMed Central Google Scholar
• Sawey, E. T. et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening. Cancer Cell 19, 347–358 (2011).
  CAS PubMed PubMed Central Google Scholar
• Hyeon, J., Ahn, S., Lee, J. J., Song, D. H. & Park, C. K. Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma. Dig. Dis. Sci. 58, 1916–1922 (2013).
  CAS PubMed Google Scholar
• Latasa, M. U. et al. Regulation of amphiregulin gene expression by β-catenin signaling in human hepatocellular carcinoma cells: a novel crosstalk between FGF19 and the EGFR system. PLoS ONE 7, e52711 (2012).
  CAS PubMed PubMed Central Google Scholar
• Uriarte, I. et al. Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development. Int. J. Cancer 136, 2469–2475 (2015).
  CAS PubMed Google Scholar
• Pai, R. et al. Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating β-catenin signaling. Cancer Res. 68, 5086–5095 (2008).
  CAS PubMed Google Scholar
• French, D. M. et al. Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS ONE 7, e36713 (2012).
  CAS PubMed PubMed Central Google Scholar
• Desnoyers, L. R. et al. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 27, 85–97 (2008).
  CAS PubMed Google Scholar
• Pai, R. et al. Antibody-mediated inhibition of fibroblast growth factor 19 results in increased bile acids synthesis and ileal malabsorption of bile acids in cynomolgus monkeys. Toxicol. Sci. 126, 446–456 (2012).
  CAS PubMed Google Scholar
• Hagel, M. et al. First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway. Cancer Discov. 5, 424–437 (2015).
  CAS PubMed Google Scholar
• Wu, X. et al. C-terminal tail of FGF19 determines its specificity toward Klotho co-receptors. J. Biol. Chem. 283, 33304–33309 (2008).
  CAS PubMed PubMed Central Google Scholar
• Zhou, M. et al. Separating tumorigenicity from bile acid regulatory activity for endocrine hormone FGF19. Cancer Res. 74, 3306–3316 (2014).
  CAS PubMed Google Scholar
• Lundasen, T. et al. PPARα is a key regulator of hepatic FGF21. Biochem. Biophys. Res. Commun. 360, 437–440 (2007).
  CAS PubMed Google Scholar
• Patel, R. et al. Glucocorticoids regulate the metabolic hormone FGF21 in a feed-forward loop. Mol. Endocrinol. 29, 213–223 (2015).
  PubMed Google Scholar
• Cyphert, H. A. et al. Activation of the farnesoid X receptor induces hepatic expression and secretion of fibroblast growth factor 21. J. Biol. Chem. 287, 25123–25138 (2012).
  CAS PubMed PubMed Central Google Scholar
• Li, Y., Wong, K., Walsh, K., Gao, B. & Zang, M. Retinoic acid receptor β stimulates hepatic induction of fibroblast growth factor 21 to promote fatty acid oxidation and control whole-body energy homeostasis in mice. J. Biol. Chem. 288, 10490–10504 (2013).
  CAS PubMed PubMed Central Google Scholar
• Adams, A. C. et al. Thyroid hormone regulates hepatic expression of fibroblast growth factor 21 in a _PPAR_α-dependent manner. J. Biol. Chem. 285, 14078–14082 (2010).
  CAS PubMed PubMed Central Google Scholar
• Oishi, K. & Tomita, T. Thiazolidinediones are potent inducers of fibroblast growth factor 21 expression in the liver. Biol. Pharm. Bull. 34, 1120–1121 (2011).
  CAS PubMed Google Scholar
• Li, H. et al. Sodium butyrate stimulates expression of fibroblast growth factor 21 in liver by inhibition of histone deacetylase 3. Diabetes 61, 797–806 (2012).
  CAS PubMed PubMed Central Google Scholar
• Nygaard, E. B., Vienberg, S. G., Orskov, C., Hansen, H. S. & Andersen, B. Metformin stimulates FGF21 expression in primary hepatocytes. Exp. Diabetes Res. 2012, 465282 (2012).
  PubMed PubMed Central Google Scholar
• Oishi, K., Konishi, M., Murata, Y. & Itoh, N. Time-imposed daily restricted feeding induces rhythmic expression of Fgf21 in white adipose tissue of mice. Biochem. Biophys. Res. Commun. 412, 396–400 (2011).
  CAS PubMed Google Scholar
• Dutchak, P. A. et al. Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones. Cell 148, 556–567 (2012).
  CAS PubMed PubMed Central Google Scholar
• Wang, H., Qiang, L. & Farmer, S. R. Identification of a domain within peroxisome proliferator-activated receptor γ regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes. Mol. Cell. Biol. 28, 188–200 (2008).
  PubMed Google Scholar
• Hondares, E. et al. Thermogenic activation induces FGF21 expression and release in brown adipose tissue. J. Biol. Chem. 286, 12983–12990 (2011).
  CAS PubMed PubMed Central Google Scholar
• Fisher, F. M. et al. FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis. Genes Dev. 26, 271–281 (2012).
  CAS PubMed PubMed Central Google Scholar
• Luo, Y. & McKeehan, W. L. Stressed liver and muscle call on adipocytes with FGF21. Front. Endocrinol. 4, 194 (2013).
  Google Scholar
• Keipert, S. et al. Skeletal muscle mitochondrial uncoupling drives endocrine cross-talk through the induction of FGF21 as a myokine. Am. J. Physiol. Endocrinol. Metab. 306, E469–E482 (2014).
  CAS PubMed Google Scholar
• Adams, A. C. et al. The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue. Mol. Metab. 2, 31–37 (2012).
  CAS PubMed PubMed Central Google Scholar
• Foltz, I. N. et al. Treating diabetes and obesity with an FGF21-mimetic antibody activating the βKlotho/FGFR1c receptor complex. Sci Transl Med. 4, 162ra153 (2012).
  PubMed Google Scholar
• Holland, W. L. et al. An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell. Metab. 17, 790–797 (2013).
  CAS PubMed PubMed Central Google Scholar
• Lin, Z. et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell. Metab. 17, 779–789 (2013).
  CAS PubMed Google Scholar
• Kersten, S. et al. Peroxisome proliferator-activated receptor α mediates the adaptive response to fasting. J. Clin. Invest. 103, 1489–1498 (1999).
  CAS PubMed PubMed Central Google Scholar
• Leone, T. C., Weinheimer, C. J. & Kelly, D. P. A critical role for the peroxisome proliferator-activated receptor α (PPARα) in the cellular fasting response: the PPARα-null mouse as a model of fatty acid oxidation disorders. Proc. Natl Acad. Sci. USA 96, 7473–7478 (1999).
  CAS PubMed PubMed Central Google Scholar
• Markan, K. R. et al. Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. Diabetes 63, 4057–4063 (2014).
  CAS PubMed PubMed Central Google Scholar
• Berglund, E. D. et al. Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology 150, 4084–4093 (2009).
  CAS PubMed PubMed Central Google Scholar
• Emanuelli, B. et al. Interplay between FGF21 and insulin action in the liver regulates metabolism. J. Clin. Invest. 124, 515–527 (2014).
  CAS PubMed PubMed Central Google Scholar
• Bookout, A. L. et al. FGF21 regulates metabolism and circadian behavior by acting on the nervous system. Nat. Med. 19, 1147–1152 (2013).
  CAS PubMed PubMed Central Google Scholar
• Liang, Q. et al. FGF21 maintains glucose homeostasis by mediating the cross talk between liver and brain during prolonged fasting. Diabetes 63, 4064–4075 (2014). This is the first evidence that glucose homeostasis is maintained by fine tuning the inter-organ crosstalk between the liver and brain, and that FGF21 has a role in this setting.
  CAS PubMed Google Scholar
• Bell, G. I. and Polonsky, K. S. Diabetes mellitus and genetically programmed defects in β-cell function. Nature 414, 788–791 (2001).
  CAS PubMed Google Scholar
• So, W. Y. et al. High glucose represses β-klotho expression and impairs fibroblast growth factor 21 action in mouse pancreatic islets: involvement of peroxisome proliferator-activated receptor γ signaling. Diabetes 62, 3751–3759 (2013).
  CAS PubMed PubMed Central Google Scholar
• Kharitonenkov, A. et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148, 774–781 (2007).
  CAS PubMed Google Scholar
• So, W. Y., Cheng, G., Xu, A., Lam, K. S. L. & Leung, P. S. Loss of fibroblast growth factor 21 action induces insulin resistance, pancreatic islet hyperplasia and dysfunction in mice. Cell Death Dis. 6, e1707 (2015).
  CAS PubMed PubMed Central Google Scholar
• Johnson, C. L. et al. Fibroblast growth factor 21 reduces the severity of cerulein-induced pancreatitis in mice. Gastroenterology 137, 1795–1804 (2009).
  CAS PubMed Google Scholar
• Inagaki, T. et al. Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell. Metab. 8, 77–83 (2008).
  CAS PubMed PubMed Central Google Scholar
• Zhang, J. & Li, Y. Fibroblast growth factor 21, the endocrine FGF pathway and novel treatments for metabolic syndrome. Drug Discov. Today 19, 579–589 (2014).
  CAS PubMed Google Scholar
• Zhang, Y. et al. The starvation hormone, fibroblast growth factor-21, extends lifespan in mice. eLife 1, e00065 (2012).
  PubMed PubMed Central Google Scholar
• De Sousa-Coelho, A. L. et al. FGF21 mediates the lipid metabolism response to amino acid starvation. J. Lipid Res. 54, 1786–1797 (2013).
  CAS PubMed PubMed Central Google Scholar
• Laeger, T. et al. FGF21 is an endocrine signal of protein restriction. J. Clin. Invest. 124, 3913–3922 (2014).
  CAS PubMed PubMed Central Google Scholar
• Ahmadian, M. et al. PPARγ signaling and metabolism: the good, the bad and the future. Nat. Med. 19, 557–566 (2013).
  CAS PubMed Google Scholar
• Adams, A. C. et al. Fibroblast growth factor 21 is not required for the antidiabetic actions of the thiazoladinediones. Mol. Metab. 2, 205–214 (2013).
  CAS PubMed PubMed Central Google Scholar
• Wei, W. et al. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ. Proc. Natl Acad. Sci. USA 109, 3143–3148 (2012).
  CAS PubMed PubMed Central Google Scholar
• Veniant, M. M. et al. Pharmacological effects of FGF21 are independent of the 'browning' of white adipose tissue. Cell. Metab. 21, 731–738 (2015).
  CAS PubMed Google Scholar
• Samms, R. J. et al. Discrete aspects of FGF21 in vivo pharmacology do not require UCP1. Cell. Reports 11, 991–999 (2015).
  CAS PubMed Google Scholar
• Lee, P., Swarbrick, M. M. & Greenfield, J. R. The sum of all browning in FGF21 therapeutics. Cell. Metab. 21, 795–796 (2015).
  CAS PubMed Google Scholar
• Owen, B. M., Mangelsdorf, D. J. & Kliewer, S. A. Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21. Trends Endocrinol. Metab. 26, 22–29 (2015).
  CAS PubMed Google Scholar
• Sarruf, D. A. et al. Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes 59, 1817–1824 (2010).
  CAS PubMed PubMed Central Google Scholar
• Owen, B. M. et al. FGF21 contributes to neuroendocrine control of female reproduction. Nat. Med. 19, 1153–1156 (2013).
  CAS PubMed PubMed Central Google Scholar
• Owen, B. M. et al. FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. Cell. Metab. 20, 670–677 (2014).
  CAS PubMed PubMed Central Google Scholar
• Yan, X. et al. FGF21 deletion exacerbates diabetic cardiomyopathy by aggravating cardiac lipid accumulation. J. Cell. Mol. Med. 19, 1557–1568 (2015).
  CAS PubMed PubMed Central Google Scholar
• Planavila, A. et al. Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat. Commun. 4, 2019 (2013).
  CAS PubMed Google Scholar
• Planavila, A. et al. Fibroblast growth factor 21 protects the heart from oxidative stress. Cardiovasc. Res. 106, 19–31 (2015).
  CAS PubMed Google Scholar
• Liu, S. Q. et al. Endocrine protection of ischemic myocardium by FGF21 from the liver and adipose tissue. Sci. Rep. 3, 2767 (2013).
  PubMed PubMed Central Google Scholar
• Galman, C. et al. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARα activation in man. Cell. Metab. 8, 169–174 (2008).
  PubMed Google Scholar
• Oishi, K., Uchida, D. & Ishida, N. Circadian expression of FGF21 is induced by PPARα activation in the mouse liver. FEBS Lett. 582, 3639–3642 (2008).
  CAS PubMed Google Scholar
• Andersen, B., Beck-Nielsen, H. & Hojlund, K. Plasma FGF21 displays a circadian rhythm during a 72-h fast in healthy female volunteers. Clin. Endocrinol. 75, 514–519 (2011).
  CAS Google Scholar
• Yu, H. et al. Circadian rhythm of circulating fibroblast growth factor 21 is related to diurnal changes in fatty acids in humans. Clin. Chem. 57, 691–700 (2011).
  CAS PubMed Google Scholar
• Lee, S. A. et al. Various oscillation patterns of serum fibroblast growth factor 21 concentrations in healthy volunteers. Diabetes Metab. J. 36, 29–36 (2012).
  PubMed PubMed Central Google Scholar
• Christodoulides, C., Dyson, P., Sprecher, D., Tsintzas, K. & Karpe, F. Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonists but not ketosis in man. J. Clin. Endocrinol. Metab. 94, 3594–3601 (2009).
  CAS PubMed Google Scholar
• Dushay, J. et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 139, 456–463 (2010).
  CAS PubMed Google Scholar
• Mraz, M. et al. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin. Endocrinol. 71, 369–375 (2009).
  CAS Google Scholar
• Hondares, E. et al. Fibroblast growth factor-21 is expressed in neonatal and pheochromocytoma-induced adult human brown adipose tissue. Metabolism 63, 312–317 (2014).
  CAS PubMed Google Scholar
• Lee, P. et al. Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans. Cell. Metab. 19, 302–309 (2014).
  CAS PubMed PubMed Central Google Scholar
• Lin, Z. et al. Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS ONE 5, e15534 (2010).
  CAS PubMed PubMed Central Google Scholar
• Dostalova, I. et al. Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. J. Clin. Endocrinol. Metab. 93, 3627–3632 (2008).
  CAS PubMed Google Scholar
• Kharitonenkov, A. & Adams, A. C. Inventing new medicines: the FGF21 story. Mol. Metab. 3, 221–229 (2014).
  CAS PubMed Google Scholar
• Woo, Y. C., Xu, A., Wang, Y. & Lam, K. S. Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives. Clin. Endocrinol. 78, 489–496 (2013).
  CAS Google Scholar
• Adams, A. C. et al. LY2405319, an engineered FGF21 variant, improves the metabolic status of diabetic monkeys. PLoS ONE 8, e65763 (2013).
  CAS PubMed PubMed Central Google Scholar
• Veniant, M. M. et al. Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys. Endocrinology 153, 4192–4203 (2012).
  CAS PubMed Google Scholar
• Nygaard, E. B., Moller, C. L., Kievit, P., Grove, K. L. & Andersen, B. Increased fibroblast growth factor 21 expression in high-fat diet-sensitive non-human primates (Macaca mulatta). Int. J. Obes 38, 183–191 (2014).
  CAS Google Scholar
• Fisher, F. M. et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 59, 2781–2789 (2010).
  CAS PubMed PubMed Central Google Scholar
• Gimeno, R. E. & Moller, D. E. FGF21-based pharmacotherapy — potential utility for metabolic disorders. Trends Endocrinol. Metab. 25, 303–311 (2014).
  CAS PubMed Google Scholar
• Hecht, R. et al. Rationale-based engineering of a potent long-acting FGF21 analog for the treatment of type 2 diabetes. PLoS ONE 7, e49345 (2012).
  CAS PubMed PubMed Central Google Scholar
• Kharitonenkov, A. et al. Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319. PLoS ONE 8, e58575 (2013).
  CAS PubMed PubMed Central Google Scholar
• Mu, J. et al. FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents. Diabetes 61, 505–512 (2012).
  CAS PubMed PubMed Central Google Scholar
• Xu, J. et al. Polyethylene glycol modified FGF21 engineered to maximize potency and minimize vacuole formation. Bioconjug. Chem. 24, 915–925 (2013).
  CAS PubMed Google Scholar
• Huang, Z. et al. A better anti-diabetic recombinant human fibroblast growth factor 21 (rhFGF21) modified with polyethylene glycol. PLoS ONE 6, e20669 (2011).
  CAS PubMed PubMed Central Google Scholar
• Camacho, R. C., Zafian, P. T., Achanfuo-Yeboah, J., Manibusan, A. & Berger, J. P. Pegylated Fgf21 rapidly normalizes insulin-stimulated glucose utilization in diet-induced insulin resistant mice. Eur. J. Pharmacol. 715, 41–45 (2013).
  CAS PubMed Google Scholar
• Song, L. et al. A solid-phase PEGylation strategy for protein therapeutics using a potent FGF21 analog. Biomaterials 35, 5206–5215 (2014).
  CAS PubMed Google Scholar
• Huang, J. et al. Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation to a scaffold antibody. J. Pharmacol. Exp. Ther. 346, 270–280 (2013).
  CAS PubMed Google Scholar
• Weng, Y. et al. Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese mice. PLoS ONE 10, e0119104 (2015).
  PubMed PubMed Central Google Scholar
• Giragossian, C. et al. Mechanistic investigation of the pre-clinical pharmacokinetics and interspecies scaling of PF-05231023, a fibroblast growth factor 21-antibody protein conjugate. Drug Metab. Dispos. 43, 803–811 (2015).
  CAS PubMed Google Scholar
• Doppalapudi, V. R. et al. Chemical generation of bispecific antibodies. Proc. Natl Acad. Sci. USA 107, 22611–22616 (2010).
  CAS PubMed PubMed Central Google Scholar
• Wu, A. L. et al. Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. Sci Transl. Med. 3, 113ra126 (2011).
  PubMed Google Scholar
• Smith, R. et al. FGF21 can be mimicked in vitro and in vivo by a novel anti-FGFR1c/β-Klotho bispecific protein. PLoS ONE 8, e61432 (2013).
  CAS PubMed PubMed Central Google Scholar
• Kolek, O. I. et al. 1α,25-dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am. J. Physiol. Gastrointest. Liver Physiol. 289, G1036–G1042 (2005).
  CAS PubMed Google Scholar
• Yu, X., Sabbagh, Y., Davis, S. I., Demay, M. B. & White, K. E. Genetic dissection of phosphate- and vitamin D-mediated regulation of circulating Fgf23 concentrations. Bone 36, 971–977 (2005).
  CAS PubMed Google Scholar
• Shimada, T. et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem. Biophys. Res. Commun. 314, 409–414 (2004).
  CAS PubMed Google Scholar
• Meir, T. et al. Parathyroid hormone activates the orphan nuclear receptor Nurr1 to induce FGF23 transcription. Kidney Int. 86, 1106–1115 (2014).
  CAS PubMed Google Scholar
• Lanske, B. & Razzaque, M. S. Molecular interactions of FGF23 and PTH in phosphate regulation. Kidney Int. 86, 1072–1074 (2014).
  CAS PubMed PubMed Central Google Scholar
• Lavi-Moshayoff, V., Wasserman, G., Meir, T., Silver, J. & Naveh-Many, T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am. J. Physiol. Renal Physiol. 299, F882–F889 (2010).
  CAS PubMed Google Scholar
• Ben-Dov, I. Z. et al. The parathyroid is a target organ for FGF23 in rats. J. Clin. Invest. 117, 4003–4008 (2007).
  CAS PubMed PubMed Central Google Scholar
• Galitzer, H., Ben-Dov, I., Lavi-Moshayoff, V., Naveh-Many, T. & Silver, J. Fibroblast growth factor 23 acts on the parathyroid to decrease parathyroid hormone secretion. Curr. Opin. Nephrol. Hypertens. 17, 363–367 (2008).
  CAS PubMed Google Scholar
• Shimada, T. et al. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am. J. Physiol. Renal Physiol. 289, F1088–F1095 (2005).
  CAS PubMed Google Scholar
• Tsuji, K., Maeda, T., Kawane, T., Matsunuma, A. & Horiuchi, N. Leptin stimulates fibroblast growth factor 23 expression in bone and suppresses renal 1α,25-dihydroxyvitamin D3 synthesis in leptin-deficient ob/ob mice. J. Bone Miner. Res. 25, 1711–1723 (2010).
  CAS PubMed Google Scholar
• Haussler, M. R. et al. The role of vitamin D in the FGF23, klotho, and phosphate bone-kidney endocrine axis. Rev. Endocr. Metab. Disord. 13, 57–69 (2012).
  CAS PubMed PubMed Central Google Scholar
• Shimada, T. et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J. Bone Miner. Res. 19, 429–435 (2004).
  CAS PubMed Google Scholar
• Kuro-o, M. et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390, 45–51 (1997). This is the first paper to describe the discovery of α-klotho.
  CAS PubMed Google Scholar
• Drüeke, T. B. & Prié, D. Klotho spins the thread of life — what does klotho do to the receptor of fibroblast growth factor-23 (FGF23)? Nephrol. Dial. Transplant 22, 1524–1526 (2007).
  PubMed Google Scholar
• Farrow, E. G. & White, K. E. Recent advances in renal phosphate handling. Nat. Rev. Nephrol. 6, 207–217 (2010).
  PubMed PubMed Central Google Scholar
• Hu, M. C. et al. Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J. 24, 3438–3450 (2010).
  CAS PubMed PubMed Central Google Scholar
• Andrukhova, O. et al. FGF23 acts directly on renal proximal tubules to induce phosphaturia through activation of the ERK1/2-SGK1 signaling pathway. Bone 51, 621–628 (2012).
  CAS PubMed PubMed Central Google Scholar
• Razzaque, M. S. & Lanske, B. Hypervitaminosis D and premature aging: lessons learned from Fgf23 and Klotho mutant mice. Trends Mol. Med. 12, 298–305 (2006).
  CAS PubMed Google Scholar
• Hesse, M., Fröhlich, L. F., Zeitz, U., Lanske, B. & Erben, R. G. Ablation of vitamin D signaling rescues bone, mineral, and glucose homeostasis in Fgf-23 deficient mice. Matrix Biol. 26, 75–84 (2007).
  CAS PubMed Google Scholar
• Ohnishi, M., Nakatani, T., Lanske, B. & Razzaque, M. S. Reversal of mineral ion homeostasis and soft-tissue calcification of klotho knockout mice by deletion of vitamin D 1α-hydroxylase. Kidney Int. 75, 1166–1172 (2009).
  CAS PubMed PubMed Central Google Scholar
• Barthel, T. K. et al. 1,25-Dihydroxyvitamin D3/VDR-mediated induction of FGF23 as well as transcriptional control of other bone anabolic and catabolic genes that orchestrate the regulation of phosphate and calcium mineral metabolism. J. Steroid Biochem. Mol. Biol. 103, 381–388 (2007).
  CAS PubMed Google Scholar
• Bai, X., Miao, D., Li, J., Goltzman, D. & Karaplis, A. C. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 145, 5269–5279 (2004).
  CAS PubMed Google Scholar
• Gutiérrez, O. M. et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med. 359, 584–592 (2008).
  PubMed PubMed Central Google Scholar
• Galitzer, H., Ben-Dov, I. Z., Silver, J. & Naveh-Many, T. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int. 77, 211–218 (2010).
  CAS PubMed Google Scholar
• Komaba, H. et al. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int. 77, 232–238 (2010).
  CAS PubMed Google Scholar
• Hofman-Bang, J., Martuseviciene, G., Santini, M. A., Olgaard, K. & Lewin, E. Increased parathyroid expression of klotho in uremic rats. Kidney Int. 78, 1119–1127 (2010).
  CAS PubMed Google Scholar
• Mirza, M. A. et al. Relationship between circulating FGF23 and total body atherosclerosis in the community. Nephrol. Dial. Transplant 24, 3125–3131 (2009).
  CAS PubMed Google Scholar
• Mirza, M. A., Larsson, A., Melhus, H., Lind, L. & Larsson, T. E. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 207, 546–551 (2009).
  CAS PubMed Google Scholar
• Gutiérrez, O. M. et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119, 2545–2552 (2009).
  PubMed PubMed Central Google Scholar
• Faul, C. et al. FGF23 induces left ventricular hypertrophy. J. Clin. Invest. 121, 4393–4408 (2011).
  CAS PubMed PubMed Central Google Scholar
• Touchberry, C. D. et al. FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. Am. J. Physiol. Endocrinol. Metab. 304, E863–E873 (2013).
  CAS PubMed PubMed Central Google Scholar
• Jonsson, K. B. et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N. Engl. J. Med. 348, 1656–1663 (2003).
  CAS PubMed Google Scholar
• Yamazaki, Y. et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J. Clin. Endocrinol. Metab. 87, 4957–4960 (2002).
  CAS PubMed Google Scholar
• Imel, E. A., Hui, S. L. & Econs, M. J. FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. J. Bone Miner. Res. 22, 520–526 (2007).
  CAS PubMed Google Scholar
• Mirza, M. A. et al. Relationship between circulating FGF23 and total body atherosclerosis in the community. Nephrol. Dial. Transplant 24, 3125–3131 (2009).
  CAS PubMed Google Scholar
• Quarles, L. D. Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat. Rev. Endocrinol. 8, 276–286 (2012).
  CAS PubMed PubMed Central Google Scholar
• Olauson, H. et al. Targeted deletion of Klotho in kidney distal tubule disrupts mineral metabolism. J. Am. Soc. Nephrol. 23, 1641–1651 (2012).
  CAS PubMed PubMed Central Google Scholar
• Quarles, L. D. The bone and beyond: 'Dem bones' are made for more than walking. Nat. Med. 17, 428–430 (2011).
  CAS PubMed PubMed Central Google Scholar
• Yamazaki, Y. et al. Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J. Bone Miner. Res. 23, 1509–1518 (2008).
  CAS PubMed Google Scholar
• Aono, Y. et al. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J. Bone Miner. Res. 24, 1879–1888 (2009).
  CAS PubMed Google Scholar
• Carpenter, T. O. et al. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J. Clin. Invest. 124, 1587–1597 (2014).
  CAS PubMed PubMed Central Google Scholar
• Shalhoub, V. et al. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J. Clin. Invest. 122, 2543–2553 (2012).
  CAS PubMed PubMed Central Google Scholar
• Koizumi, M., Komaba, H., Nakanishi, S., Fujimori, A. & Fukagawa, M. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol. Dial. Transplant 27, 784–790 (2012).
  CAS PubMed Google Scholar
• Gonzalez-Parra, E. et al. Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients. Nephrol. Dial. Transplant 26, 2567–2571 (2011).
  CAS PubMed Google Scholar
• Di Marco, G. S. et al. Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD. Nephrol. Dial. Transplant 29, 2028–2035 (2014).
  CAS PubMed PubMed Central Google Scholar
• Wu, A. L. et al. Antibody-mediated activation of FGFR1 induces FGF23 production and hypophosphatemia. PLoS ONE 8, e57322 (2013).
  CAS PubMed PubMed Central Google Scholar
• Muller, T. D. et al. Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21. J. Pept. Sci. 18, 383–393 (2012).
  PubMed Google Scholar